Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 07, 2020

SELL
$10.3 - $17.3 $15,089 - $25,344
-1,465 Closed
0 $0
Q1 2020

May 04, 2020

SELL
$11.0 - $31.7 $550 - $1,585
-50 Reduced 3.3%
1,465 $2,000
Q4 2019

Feb 04, 2020

BUY
$10.6 - $24.1 $2,374 - $5,398
224 Added 17.35%
1,515 $4,000
Q3 2019

Nov 12, 2019

BUY
$20.0 - $24.6 $25,820 - $31,758
1,291 New
1,291 $3,000

About Cellectar Biosciences, Inc.


  • Ticker CLRB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 6,114,290
  • Market Cap $1.47M
  • Description
  • Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...
More about CLRB
Track This Portfolio

Track Victory Capital Management Inc Portfolio

Follow Victory Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Victory Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Victory Capital Management Inc with notifications on news.